Ken Griffin Albireo Pharma, Inc. Transaction History

Citadel Advisors LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$18.01 - $23.78 $4.45 Million - $5.88 Million	-247,302 Reduced 99.13%	2,169 $46,000
Q3 2022 Nov 14, 2022	BUY	$16.32 - $26.37 $2.09 Million - $3.37 Million	127,950 Added 105.29%	249,471 $4.83 Million
Q2 2022 Aug 15, 2022	BUY	$18.54 - $37.29 $435,968 - $876,874	23,515 Added 23.99%	121,521 $2.41 Million
Q1 2022 May 16, 2022	BUY	$23.94 - $33.74 $1.66 Million - $2.33 Million	69,163 Added 239.79%	98,006 $2.92 Million
Q4 2021 Feb 14, 2022	BUY	$21.19 - $31.29 $230,377 - $340,184	10,872 Added 60.5%	28,843 $671,000

Q3 2021 Nov 15, 2021	SELL	$27.36 - $35.98 $81,095 - $106,644	-2,964 Reduced 14.16%	17,971 $561,000
Q2 2021 Aug 16, 2021	SELL	$28.9 - $36.87 $44,419 - $56,669	-1,537 Reduced 6.84%	20,935 $736,000
Q4 2020 Feb 16, 2021	SELL	$31.56 - $42.16 $3.74 Million - $4.99 Million	-118,349 Reduced 84.04%	22,472 $843,000
Q3 2020 Nov 16, 2020	BUY	$23.19 - $41.61 $2.85 Million - $5.11 Million	122,926 Added 686.93%	140,821 $4.7 Million
Q2 2020 Aug 14, 2020	BUY	$14.82 - $29.92 $105,296 - $212,581	7,105 Added 65.85%	17,895 $474,000
Q1 2020 May 15, 2020	BUY	$11.67 - $27.23 $125,919 - $293,811	10,790 New	10,790 $177,000

865

Ticker ALBO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 19,612,500
Description
Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as we...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.